Lola Cook1, Jeanine Schulze1, Catherine Kopil1, Tara Hastings1, Anna Naito1, Joanne Wojcieszek1, Katelyn Payne1, Roy N Alcalay1, Christine Klein1, Rachel Saunders-Pullman1, Tatyana Simuni1, Tatiana Foroud1. 1. Department of Medical and Molecular Genetics (LC, JS, TF), Indiana University School of Medicine, Indianapolis; The Michael J. Fox Foundation for Parkinson's Research (CK, TH), New York; Parkinson's Foundation (AN), Miami, FL; Department of Neurology (JW, KP), Indiana University School of Medicine, Indianapolis; Department of Neurology (RNA), Columbia University Irving Medical Center, New York; Institute of Neurogenetics (CK), University of Lübeck, Germany; Department of Neurology (RS-P), Mount Sinai Beth Israel, New York; and Parkinson's Disease and Movement Disorders Center (TS), Northwestern University Feinberg School of Medicine, Chicago IL.
Abstract
PURPOSE OF REVIEW: With the advent of precision medicine and demand for genomic testing information, we may question whether it is time to offer genetic testing to our patients with Parkinson disease (PD). This review updates the current genetic landscape of PD, describes what genetic testing may offer, provides strategies for evaluating whom to test, and provides resources for the busy clinician. RECENT FINDINGS: Patients with PD and their relatives, in various settings, have expressed an interest in learning their PD genetic status; however, physicians may be hesitant to widely offer testing due to the perceived low clinical utility of PD genetic test results. The rise of clinical trials available for patients with gene-specific PD and emerging information on genotype-phenotype correlations are starting to shift this discussion about testing. SUMMARY: By learning more about the various genetic testing options for PD and utility of results for patients and their care, clinicians may become more comfortable with widespread PD genetic testing in the research and clinical setting.
PURPOSE OF REVIEW: With the advent of precision medicine and demand for genomic testing information, we may question whether it is time to offer genetic testing to our patients with Parkinson disease (PD). This review updates the current genetic landscape of PD, describes what genetic testing may offer, provides strategies for evaluating whom to test, and provides resources for the busy clinician. RECENT FINDINGS: Patients with PD and their relatives, in various settings, have expressed an interest in learning their PD genetic status; however, physicians may be hesitant to widely offer testing due to the perceived low clinical utility of PD genetic test results. The rise of clinical trials available for patients with gene-specific PD and emerging information on genotype-phenotype correlations are starting to shift this discussion about testing. SUMMARY: By learning more about the various genetic testing options for PD and utility of results for patients and their care, clinicians may become more comfortable with widespread PD genetic testing in the research and clinical setting.
Authors: Carlos Velez-Pardo; Oswaldo Lorenzo-Betancor; Marlene Jimenez-Del-Rio; Sonia Moreno; Francisco Lopera; Mario Cornejo-Olivas; Luis Torres; Miguel Inca-Martinez; Pilar Mazzetti; Carlos Cosentino; Dora Yearout; Sarah M Waldherr; Cyrus P Zabetian; Ignacio F Mata Journal: Parkinsonism Relat Disord Date: 2019-02-04 Impact factor: 4.891
Authors: Lola Cook; Jeanine Schulze; Jennifer Verbrugge; James C Beck; Karen S Marder; Rachel Saunders-Pullman; Christine Klein; Anna Naito; Roy N Alcalay Journal: Parkinsonism Relat Disord Date: 2021-10-19 Impact factor: 4.891